Need Help? Chat Online or Toll Free: 1-800-891-0844
Cart (0)

Bimagrumab

What is a Generic Drug?

A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.

The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.

Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.

Coming Soon – Save up to 85%

Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.

Sign Up

Prescription Required

  • Related Products & Conditions

  • Product Details

    Description

    Bimagrumab is a fully human monoclonal antibody that acts as an activin type II receptor (ActRII) antagonist. It is designed to block ligands such as myostatin and activins that inhibit muscle growth, thereby promoting muscle mass and strength. Bimagrumab has been investigated for the treatment of conditions associated with muscle wasting and metabolic dysfunction, including sporadic inclusion body myositis (sIBM), sarcopenia, and obesity-related metabolic disorders. Although not yet FDA-approved for any indication, clinical studies have shown promise in improving body composition and glycemic control, particularly in patients with type 2 diabetes and obesity.

    Fact Table

    Formula

    C6370H9834N1698O2002S44

    License

    Not FDA-approved (investigational)

    Bioavailability

    Not orally bioavailable; administered IV

    Legal status

    Investigational (Rx-only in clinical trials)

    Chemical Name

    Bimagrumab (anti-ActRII monoclonal antibody)

    Elimination half-life

    ~24 to 26 days

    Dosage (Strength)

    Typically studied at 10 mg/kg IV every 4 weeks

    Pregnancy

    Use not established; not recommended

    Brands

    None (investigational)

    Protein binding

    High (typical of monoclonal antibodies)

    PubChem CID

    119190987

    MedlinePlus

    Not listed

    ChEBI

    Not assigned

    ATC code

    Not assigned

    DrugBank

    DB11938

    KEGG

    Not listed

    Routes of administration

    Intravenous

    Directions

    Bimagrumab is administered via intravenous (IV) infusion, typically once every four weeks. The exact dosing and treatment schedule may vary based on the indication under investigation. Clinical administration should occur under medical supervision, with pre-infusion assessment and post-infusion monitoring for adverse effects.

    Ingredients

    Active Ingredient: Bimagrumab (recombinant human monoclonal antibody targeting ActRIIA/B)

    Formulation details (as per investigational drug): Sterile solution for IV infusion, composition includes buffer agents and stabilizers appropriate for monoclonal antibody preservation. Full excipient list is proprietary pending regulatory approval.

    Contraindications

    As Bimagrumab remains an investigational product, no formal contraindications are established; however, it should not be administered to individuals with known hypersensitivity to monoclonal antibodies or any components of the investigational formulation. Use in pregnant or breastfeeding women is not recommended due to lack of safety data.

    Cautions

    Patients should be monitored for infusion-related reactions, including hypersensitivity, hypotension, and fever. The long-term safety profile remains under investigation, and caution is advised in populations with cardiovascular or renal comorbidities. As a growth-promoting agent, off-target effects on non-skeletal muscle tissues and tumorigenesis are theoretical risks and are being evaluated in ongoing studies.

    Side Effects

    In clinical trials, the following side effects have been reported:

    Infusion-related reactions

    Muscle cramps

    Headache

    Upper respiratory tract infections

    Gastrointestinal discomfort

    Transient elevations in liver enzymes

    No long-term adverse effects have been confirmed, but surveillance continues in ongoing Phase II and III trials.

    IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.

    Product Code : 14564

  • Product Reviews